|
CPSF7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.39389968853732E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.6925999996319E-07 |
| Normal-vs-Stage2 |
6.90699999972288E-07 |
| Normal-vs-Stage3 |
4.84630002794972E-10 |
| Normal-vs-Stage4 |
2.79829999949577E-07 |
| Stage1-vs-Stage2 |
7.541900E-02 |
| Stage1-vs-Stage3 |
1.251910E-02 |
| Stage1-vs-Stage4 |
1.377640E-01 |
| Stage2-vs-Stage3 |
9.780600E-01 |
| Stage2-vs-Stage4 |
5.859000E-01 |
| Stage3-vs-Stage4 |
4.903800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.68699998415178E-09 |
| Normal-vs-AfricanAmerican |
5.355700E-03 |
| Normal-vs-Asian |
2.563600E-03 |
| Caucasian-vs-AfricanAmerican |
4.024400E-01 |
| Caucasian-vs-Asian |
6.123800E-02 |
| AfricanAmerican-vs-Asian |
6.114000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.24170001742408E-09 |
| Normal-vs-Female |
4.25150004090824E-09 |
| Male-vs-Female |
6.451200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.92169999977143E-07 |
| Normal-vs-Age(41-60Yrs) |
1.1780999997768E-07 |
| Normal-vs-Age(61-80Yrs) |
2.29420038522221E-10 |
| Normal-vs-Age(81-100Yrs) |
1.400850E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.646400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.681400E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.368600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.074300E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.396400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.624800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.019460E-04 |
| Classical-VS-Follicular |
1.395590E-03 |
| Classical-VS-Other |
7.008600E-01 |
| Classical-VS-Normal |
3.94420000000562E-05 |
| Tall-VS-Follicular |
5.981000E-01 |
| Tall-VS-Other |
1.560590E-01 |
| Tall-VS-Normal |
2.44969999840805E-09 |
| Follicular-VS-Other |
4.696200E-01 |
| Follicular-VS-Normal |
2.08620000163862E-08 |
| Other-VS-Normal |
4.744100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.4059999831062E-09 |
| Normal-vs-N1 |
7.50420000000807E-05 |
| N0-vs-N1 |
2.828400E-01 |
|
|
